Nuvalent, Inc.(Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creatingpreciselytargeted therapies for clinically proven kinase targets in cancer, today announced an upcoming poster presentation further characterizing the preclinical intracranial activity of its novel HER2-selective inhibitor, NVL-330,at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics being held October 22-26, 2025 in Boston.
https://mma.prnewswire.com/media/1583941/Nuvalent_Inc_Logo_2024.jpg
Details of the poster presentation are as follows:
Title:Preclinical intracranial activity of NVL-330, a selective HER2 tyrosine kinase inhibitorAbstract Number: B057Authors:Yuting Sun*1, Kristin L. Andrews1, Anupong Tangpeerachaikul1, Michael J. Walsh1, Nancy E. Kohl2, Joshua C. Horan1, Henry E. Pelish1Session: Poster Session BSession Date and Time:Friday, October 24, 2025, 12:30-4:00 p.m. ETLocation: Exhibit Hall D
*Presenter, corresponding author;1Nuvalent, Inc.,Cambridge, MA, USA; 2Kohl Consulting, Wellesley, MA, USA
About NuvalentNuvalent, Inc. (Nasdaq: NUVL) is a clinical-stage biopharmaceutical company focused on creatingpreciselytargeted therapies for patients with cancer, designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in chemistry and structure-based drug design, we develop innovative small molecules that have the potential to overcome resistance, minimize adverse events, address brain metastases, and drive more durable responses. Nuvalent is advancing a robust pipeline with investigational candidates for ROS1-positive, ALK-positive, and HER2-altered non-small cell lung cancer, and multiple discovery-stage research programs.
https://edge.prnewswire.com/c/img/favicon.png?sn=NE96258&sd=2025-10-13
View original content to download multimedia:https://www.prnewswire.com/news-releases/nuvalent-to-present-new-preclinical-data-for-her2-selective-inhibitor-nvl-330-at-aacr-nci-eortc-international-conference-on-molecular-targets-and-cancer-therapeutics-302582286.html
SOURCE Nuvalent, Inc.
https://rt.newswire.ca/rt.gif?NewsItemId=NE96258&Transmission_Id=202510131253PR_NEWS_USPR_____NE96258&DateId=20251013